The American Cancer Society (ACS) and the Global Center for Medical Innovation (GCMI) have selected the first project to be funded under a recently launched partnership to identify, fund, and promote promising medical devices and technologies within the ACS portfolio of current or previously-funded research. The goal of the initiative is to identify and solve critical unmet needs through innovative technology solutions to diagnose and treat cancer and bring them to market.
The ACS and GCMI have selected Boston University’s BOTLab as the first oncology project to enter the program. BOTLab, short for Biomedical Optical Technologies Lab, will receive up to $100,000 to accelerate BOTLab’s near-infrared spectroscopy (NIR) technology. The aim is to use the technology to provide real-time data that can determine how well chemotherapy is working in breast cancer patients. The funding is in addition to an existing ACS grant to investigators at BOTlab, and its purpose is to accelerate high-quality commercialization of innovative medical technologies.
The initiative is part of an ACS effort to invest in later stage development projects among ACS grantees to speed the development of diagnostics, drugs, and therapies to help cancer patients. By promoting a culture of innovation and commercialization, ACS seeks
Article originally posted at